ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

lurbinectedin

Also written as “Lurbinectedin”, “lurbinectedin (PM01183)” and “Lurbinectedin (PM01183)”.

Its studies are mostly in Small Cell Lung Carcinoma · Breast Neoplasms · Neoplasms · Sarcoma, Ewing · Leiomyosarcoma, led by 5 companies.

Drug pagePM 01183: every studyMany companies study it; this page follows only the 27 they lead. All 53 studies, academic ones too, with its approvals and label.
Furthest: phase 3, since Apr 10, 201527 company-led studies, 7 open or runningNext primary completion: Dec 31, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
PharmaMar202 open or runningphase 3since Apr 10, 2015Apr 6, 2009Aug 30, 2029phase 3 · NCT06088290
Jazz Pharmaceuticalsits history only32 open or runningphase 2since Nov 8, 2021Nov 8, 2021Jan 28, 2028phase 2 · NCT05734066
Luye Pharma Groupits history only21 open or runningphase 3since Jul 3, 2024Nov 5, 2020Dec 31, 2027phase 3 · NCT06496048
Gilead Sciencesits history only11 open or runningphase 3since Jan 24, 2025Jan 24, 2025Oct 2029phase 3 · NCT06801834
Hoffmann-La Rocheits history only11 open or runningphase 3since Oct 12, 2021Oct 12, 2021none ahead

Also a collaborator on its studies: Jazz Pharmaceuticals Ireland.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of PharmaMar only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 1 study since Apr 6, 2009.

  1. Mar 9, 2011Phase 1 study in LeukemiaNCT01314599 · 45 enrolled · United States
  2. Jul 26, 2011Phase 1 study in Major Advanced Solid Tumors Other Than ColorectalNCT01405391 · 42 enrolled · United States
  3. Jan 30, 2012Phase 2 study in Breast NeoplasmsNCT01525589 · 111 enrolled · United States, Spain
  4. Apr 2, 2013Phase 1 study in Breast NeoplasmsNCT01831089 · 69 enrolled · United States, Spain, Switzerland
  5. Sep 17, 2013Phase 2 study in Carcinoma, Non-Small-Cell LungNCT01951157 · 69 enrolled · United States
  6. Oct 22, 20133 phase 1 studiesNCT01980667, NCT01970553, NCT01970540
  7. Aug 5, 2014Phase 1 study in Breast NeoplasmsNCT02210364 · 81 enrolled · Belgium, Spain
  8. Apr 10, 2015Phase 3 study in Ovarian NeoplasmsNCT02421588 · 442 enrolled · United States
  9. May 6, 20152 phase 2 studiesNCT02454972, NCT02451007
  10. Sep 24, 2015Phase 3 study in Small Cell Lung CarcinomaNCT02566993 · 613 enrolled · United States, Argentina, Austria and more
  11. Nov 5, 2015Phase 2 study in GlioblastomaNCT02611024 · 316 enrolled · United States, France, Germany and more
  12. Sep 2, 20213 phase 1 studiesNCT05072106, NCT05063318, NCT05101265
  13. Nov 29, 2021Phase 3 study in Small Cell Lung CarcinomaNCT05153239 · 705 enrolled · United States, Australia, Austria and more
  14. Sep 28, 2023Phase 3 study in LeiomyosarcomaNCT06088290 · 469 enrolled · United States, Austria, Belgium and more

Ahead

  1. Aug 30, 2029Primary completion: phase 3 study in LeiomyosarcomaNCT06088290

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 20 PharmaMar leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06088290Leiomyosarcoma · United States, Austria, Belgium and more3Active, not recruitingAug 30, 2029469
NCT05153239Small Cell Lung Carcinoma · United States, Australia, Austria and more3CompletedApr 10, 2026705
NCT05101265Advanced Solid Tumor · Spain1RecruitingJun 1, 202524
NCT05072106Advanced Solid Tumor · Spain1CompletedJan 18, 202211
NCT05063318Advanced Solid Tumors · Spain1CompletedApr 21, 202214
NCT02611024Glioblastoma · United States, France, Germany and more2CompletedJul 1, 2025316
NCT02566993Small Cell Lung Carcinoma · United States, Argentina, Austria and more3CompletedFeb 24, 2020613
NCT02451007Solid Tumors · United States, Spain2CompletedAug 19, 201639
NCT02454972Advanced Solid Tumors · United States, Belgium, France and more2CompletedSep 18, 2020345
NCT02421588Ovarian Neoplasms · United States3CompletedOct 12, 2018442
NCT02210364Breast Neoplasms · Belgium, Spain1CompletedOct 201681
NCT01980667Neoplasms · Switzerland, United Kingdom1CompletedJan 5, 201741
NCT01970553Neoplasms · Spain, United Kingdom1CompletedOct 201347
NCT01970540Neuroendocrine Tumors · Spain, United Kingdom1CompletedAug 9, 2017122
NCT01951157Carcinoma, Non-Small-Cell Lung · United States2CompletedNov 201669
NCT01831089Breast Neoplasms · United States, Spain, Switzerland1CompletedJul 201669
NCT01525589Breast Neoplasms · United States, Spain2CompletedOct 2018111
NCT01405391Major Advanced Solid Tumors Other Than Colorectal · United States1CompletedJan 201642
NCT01314599Leukemia · United States1CompletedJul 201545
NCT00877474ADVANCED SOLID TUMORS · United States, Spain1CompletedJun 201130

How it is read

Names in the registry

  • “Lurbinectedin”, 13 entries
  • “lurbinectedin (PM01183)”, 6 entries
  • “Lurbinectedin (PM01183)”, 3 entries
  • “PM01183”, 3 entries
  • “Lurbinectedin (regions/countries where approved and available)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.